US Stock MarketDetailed Quotes

ELTX Elicio Therapeutics

Watchlist
  • 7.470
  • +1.020+15.81%
Close Jan 22 16:00 ET
  • 7.460
  • -0.010-0.13%
Post 19:50 ET
80.61MMarket Cap-1.72P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    15 hours ago
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
    Wednesday, 22nd January at 7:30 am
    Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis
    Phase 2 randomized study of ELI-002 fully enrolled, with formal interim analysis of disease-free survival ("DFS") expected in H1 2025; positive results could support rapid advan...
    Trytosaveabit
    Trytosaveabit
    Dec 12, 2024 06:13
    Update
    $Elicio Therapeutics (ELTX.US)$ Elicio Therapeutics Presents Updated Results From ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
    GlobeNewswire· 12 mins ago
    Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
    Strong correlation observed between mRFS and strength of T cell response
    Event-driven interim analysis from randomized Phase 2 trial expected in H1 2025
    Jaguar8
    Jaguar8
    Dec 12, 2024 06:04
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
    Thursday, 12th December at 7:00 am
    Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
    Strong correlation observed between mRFS and strength of T cell response
    Event-driven interim analysis from randomized Phase 2 trial expected in H1 20...
    Jaguar8
    Jaguar8
    Dec 3, 2024 06:05
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
    Tuesday, 3rd December at 7:00 am
    BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ: ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the completion of enrollment in the Phase 2 AMPLIFY-7P study (NCT05726864). The randomized Phase 2 st...
    Jaguar8
    Jaguar8
    Nov 7, 2024 15:06
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
    Elicio Therapeutics presented updated preliminary results from the AMPLIFY-7P Phase 1 clinical trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumors. Key findings show mKRAS-specific T cell responses in all evaluable patients, with the 4.9 mg dose group showing 12-fold higher ...
Read more

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
Fuling Technology
001356
+371.32%
KLT
831689
+23.60%
Hand Enterprise Solutions
300170
+20.00%
4
Kinco Automation (Shanghai) Co.,Ltd
688160
+17.15%
5
Doushen(Beijing) Education & Technology Inc.
300010
+16.32%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Trump's comeback to the Office
Following Trump's Policies to Seek Investment Opportunities
Discussing
December CPI comes in as expected, is that enough?
U.S. December CPI rose 2.9% year-on-year, aligning with expectations but marking a three-month inflation increase trend. The market reacted Show More
Here's the Breakdown for December CPI, in One Chart